A phase I/II study of nivolumab, paclitaxel, and ramucirumab as second-line in advanced gastric cancer

被引：0
|
作者：
Hironaka, Shuichi
Kadowaki, Shigenori
Izawa, Naoki
Nishina, Tomohiro
Yamanaka, Takeharu
Minashi, Keiko
Muro, Kei
Sunakawa, Yu
Kajiwara, Takeshi
Hayashi, Yuichiro
Kawakami, Yutaka
Nakajima, Takako Eguchi
机构：
[1] Chiba Canc Ctr, Clin Trial Promot Dept, Chiba, Japan
[2] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan
[3] St Marianna Univ, Sch Med, Dept Clin Oncol, Kawasaki, Kanagawa, Japan
[4] Natl Hosp Org Shikoku Canc Ctr, Matsuyama, Ehime, Japan
[5] Yokohama City Univ, Sch Med, Yokohama, Kanagawa, Japan
[6] Canc Ctr Hosp, Dept Clin Oncol, Nagoya, Aichi, Japan
[7] USC Keck Sch Med, Norris Comprehens Canc Ctr, Los Angeles, CA USA
[8] Natl Hosp Org Shikoku Canc Ctr, Dept Gastrointestinal Med Oncol, Matsuyama, Ehime, Japan
[9] Keio Univ, Sch Med, Tokyo, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
352
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Results of a phase II trial of ramucirumab plus irinotecan as second-line treatment for patients with advanced gastric cancer (HGCSG 1603)
    Kawamoto, Yasuyuki
    Yuki, Satoshi
    Sawada, Kentaro
    Nakamura, Michio
    Muto, Osamu
    Sogabe, Susumu
    Shindo, Yoshiaki
    Ishiguro, Atsushi
    Sato, Atsushi
    Tsuji, Yasushi
    Dazai, Masayoshi
    Okuda, Hiroyuki
    Sasaki, Takahide
    Harada, Kazuaki
    Nakano, Shintaro
    Nakatsumi, Hiroshi
    Sekiguchi, Mari
    Sakata, Yuh
    Sakamoto, Naoya
    Komatsu, Yoshito
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [32] Phase II Study of Ramucirumab Plus Irinotecan Combination Therapy as Second-Line Treatment in Patients with Advanced Gastric Cancer: HGCSG1603
    Kawamoto, Yasuyuki
    Yuki, Satoshi
    Sawada, Kentaro
    Nakamura, Michio
    Muto, Osamu
    Sogabe, Susumu
    Shindo, Yoshiaki
    Ishiguro, Atsushi
    Sato, Atsushi
    Tsuji, Yasushi
    Dazai, Masayoshi
    Okuda, Hiroyuki
    Meguro, Takashi
    Harada, Kazuaki
    Sekiguchi, Mari
    Okada, Kazufumi
    Ito, Yoichi M.
    Sakata, Yuh
    Sakamoto, Naoya
    Komatsu, Yoshito
    ONCOLOGIST, 2022, 27 (08): : E642 - E649
  • [33] Weekly paclitaxel as second-line chemotherapy for advanced or recurrent gastric cancer
    Hironaka S.
    Zenda S.
    Boku N.
    Fukutomi A.
    Yoshino T.
    Onozawa Y.
    Gastric Cancer, 2006, 9 (1) : 14 - 18
  • [34] Second-line chemotherapy with paclitaxel for elderly patients with advanced gastric cancer
    Ohba, Akihiro
    Takashima, Atsuo
    Nishiuchi, Takamasa
    Honma, Yoshitaka
    Iwasa, Satoru
    Okita, Natsuko
    Kato, Ken
    Hamaguchi, Tetsuya
    Nagashima, Kengo
    Boku, Narikazu
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [35] Efficacy and safety of nab-paclitaxel plus ramucirumab versus paclitaxel plus ramucirumab as second-line treatment for patients with advanced gastric cancer: A single institutional experience
    Okunaka, Mashiro
    Kotani, Daisuke
    Demachi, Ken
    Kawazoe, Akihito
    Yoshino, Takayuki
    Shitara, Kohei
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [36] Multicenter phase Ib/II study of second-line trastuzumab, ramucirumab, and paclitaxel in patients with HER2-positive advanced gastric or gastroesophageal junction cancer (HER-RAM study).
    Rha, Sun Young
    Kim, Chang Gon
    Jung, Minkyu
    Kim, Hyo Song
    Lee, Choong-kun
    Jeung, Hei-Cheul
    Koo, Dong-Hoe
    Bae, Woo Kyun
    Zang, Dae Young
    Kim, Hyunki
    Chung, Hyun Cheol Cheol
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [37] Nab-paclitaxel as second-line treatment in advanced gastric cancer: a multicenter phase II study of the Hellenic Oncology Research Group
    Katsaounis, Panagiotis
    Kotsakis, Athanasios
    Kentepozidis, Nikolaos
    Polyzos, Aris
    Bakogeorgos, Marios
    Koinis, Filippos
    Vamvakas, Lambros
    Vardakis, Nikolaos
    Kalbakis, Kostas
    Boukovinas, Ioannis
    Varthalitis, Ioannis I.
    Prinarakis, Efthimios
    Georgoulias, Vassilis
    Souglakos, John
    ANNALS OF GASTROENTEROLOGY, 2018, 31 (01): : 65 - 70
  • [38] A phase I/II trial of second-line chemotherapy with paclitaxel and irinotecan in fluoropyrimidine- and platinum-pretreated patients with advanced gastric cancer
    Jin Won Kim
    In Sil Choi
    Yu Jung Kim
    Kyung-Hun Lee
    Keun-Wook Lee
    Tae-Yong Kim
    Sae-Won Han
    Jee Hyun Kim
    Tae-You Kim
    Jong Seok Lee
    Yung-Jue Bang
    Seock-Ah Im
    Do-Youn Oh
    Cancer Chemotherapy and Pharmacology, 2015, 75 : 1175 - 1182
  • [39] A phase I/II trial of second-line chemotherapy with paclitaxel and irinotecan in fluoropyrimidine- and platinum-pretreated patients with advanced gastric cancer
    Kim, Jin Won
    Choi, In Sil
    Kim, Yu Jung
    Lee, Kyung-Hun
    Lee, Keun-Wook
    Kim, Tae-Yong
    Han, Sae-Won
    Kim, Jee Hyun
    Kim, Tae-You
    Lee, Jong Seok
    Bang, Yung-Jue
    Im, Seock-Ah
    Oh, Do-Youn
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 75 (06) : 1175 - 1182
  • [40] HGCSG 1603: A phase 2 trial of ramucirumab plus irinotecan as second-line treatment for advanced gastric cancer
    Sawada, Kentaro
    Kawamoto, Yasuyuki
    Yuki, Satoshi
    Nakamura, Michio
    Muto, Osamu
    Sogabe, Susumu
    Shindo, Ysohiaki
    Ishiguro, Atsushi
    Sato, Atsushi
    Tsuji, Yasushi
    Dazai, Masayoshi
    Okuda, Hiroyuki
    Sasaki, Takahide
    Harada, Kazuaki
    Nakano, Shintaro
    Nakatsumi, Hiroshi
    Sekiguchi, Mari
    Sakata, Yuh
    Sakamoto, Naoya
    Komatsu, Yoshito
    ANNALS OF ONCOLOGY, 2021, 32 : S314 - S314
12345